Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company reported a steady performance in H1 2025, with revenue and net profit reaching 1.38 billion and 117 million yuan, respectively, representing year-on-year growth of 8.39% and 7.53% [4] - The growth in revenue was driven by the C-end product "Kongke" and stable development in B-end business, with significant contributions from various product lines [5] - The company is expanding its product matrix and actively exploring new sales channels, which is expected to support future growth [9] Summary by Sections Financial Performance - In H1 2025, the company achieved revenue of 1.38 billion yuan and net profit of 117 million yuan, with Q2 showing a revenue of 711 million yuan and net profit of 58 million yuan, indicating a quarter-on-quarter acceleration [4][5] - The revenue from compound seasonings, light cooking solutions, and beverage dessert ingredients in H1 2025 was 630 million, 636 million, and 80 million yuan, respectively, with year-on-year growth rates of 4.06%, 13.94%, and 6.92% [5] Regional Performance - Revenue growth in H1 2025 varied by region, with significant increases in South China (58.63%) and Northwest (72.00%), while North China experienced a decline of 7.60% [5] Sales Model - Direct sales and non-direct sales generated revenues of 1.13 billion and 210 million yuan in H1 2025, with year-on-year growth of 9.95% and 2.49% [6] Profitability - The company's gross margin improved to 33.68%, up 1.61 percentage points year-on-year, driven by a higher proportion of C-end "Kongke" business [7] - The net profit margin remained stable at 8.45%, with a slight increase in the net profit margin excluding non-recurring items to 8.06% [7] Product and Channel Development - The company is enhancing its product offerings and expanding its distribution channels, including entering O2O retail and major membership-based stores [8] - New production capacity has been established to support growth, including a new intelligent production base planned in Shanghai [8] Earnings Forecast and Valuation - The forecast for net profit in 2025 has been slightly adjusted to 264 million yuan, with EPS estimates of 0.66 yuan for 2025 [9] - The current stock price corresponds to a PE ratio of 22x for 2025, reflecting the company's growth potential [9]

2025 年 8 月 31 日 公司研究 业绩环比改善，订单复苏强劲 ——普蕊斯（301257.SZ）2025 年半年报点评 要点 事件：公司发布 2025 年半年报，实现营业收入 3.9 亿元（YOY- 1.08%）；实 现归母净利润 5415.61 万元（YOY-1.40%）；业绩符合预期。 业绩环比改善，项目储备充足。25Q2 公司实现营业收入 2.14 亿元，环比增加 21.06%；实现归母净利润 0.47 亿，环比增加 528.73%；毛利率环比提升 13.44pp 至 29.67%，发展态势良好，整体反映公司业绩在 25Q2 出现明显改善。截至 25H1，公司累计承接国际和国内 SMO 项目超 4000 个，在执行项目达 2428 个， 较 2024 年底显著增长。在前沿治疗领域持续突破，累计参与 ADC 项目 140 个、 CGT 项目 73 个，项目储备充足。 订单复苏强劲，合同储备创历史新高。25H1 行业和客户需求呈现复苏迹象，公 司新签不含税合同金额 6.00 亿元，同比大幅增长 40.12%；截至 6 月末存量不 含税合同金额 19.98 亿元，同比增长 9.45%，为下半年业绩增长奠 ...

Investment Rating - The report maintains a "Buy" rating for Beijing Bank (601169.SH) with a current price of 6.00 CNY [1] Core Views - Beijing Bank's performance improved in the first half of 2025, with operating income reaching 36.22 billion CNY, a year-on-year increase of 1%, and net profit attributable to shareholders of 15.05 billion CNY, up 1.1% year-on-year [3][4] - The bank's return on equity (ROE) was 10.64%, a decrease of 0.61 percentage points year-on-year [3] Financial Performance Summary - Revenue and net profit growth improved compared to Q1, with revenue growth of 1% and net profit growth of 1.1%, up 4.2 and 3.6 percentage points respectively from Q1 [4] - Net interest income grew by 1.2%, with a 2.6 percentage point increase from Q1, while non-interest income increased by 0.5%, up 8.3 percentage points from Q1 [4] - Non-interest income accounted for 28.6% of total income, remaining stable compared to the same period last year [4] Asset and Loan Growth - Interest-earning assets and loans grew by 22.2% and 10.3% year-on-year respectively, with interest-earning asset growth increasing by 6.9 percentage points from Q1 [5] - The bank's loan structure showed a significant focus on corporate loans, with new corporate loans amounting to 153 billion CNY, an increase of 23.6 billion CNY year-on-year [6] Deposit and Liability Management - As of the end of Q2, interest-bearing liabilities and deposits grew by 21.6% and 13.3% year-on-year, with a notable increase in interest-bearing liabilities of 488.5 billion CNY in the first half [7] - The bank's net interest margin was reported at 1.31%, narrowing by 16 basis points compared to 2024 [8] Non-Interest Income and Fee Growth - Non-interest income increased by 0.5% to 10.37 billion CNY, with net fee and commission income rising by 20.4% to 2.51 billion CNY [8] - Investment income contributed significantly to non-interest income, amounting to 7.58 billion CNY, a year-on-year increase of 4.2% [8] Asset Quality and Risk Management - The non-performing loan (NPL) ratio remained stable at 1.3%, with a decrease of 1 basis point year-to-date [9] - The bank's provision coverage ratio was 195.7%, down 2.3 percentage points from Q1 [9] Profit Forecast and Valuation - The report forecasts earnings per share (EPS) for 2025-2027 at 1.28, 1.33, and 1.38 CNY respectively, with the current stock price corresponding to price-to-book (PB) ratios of 0.44, 0.41, and 0.38 [10][11]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company reported a total revenue of 1.495 billion yuan for the first half of 2025, representing a year-on-year growth of 9.5%, and a net profit of 152 million yuan, which is a 41.6% increase year-on-year [1][2] - The operating cash flow reached 300 million yuan, showing a significant increase of 111% year-on-year [1] - The company is focusing on the development of "AI avatars" for renowned doctors, which aims to enhance the quality of traditional Chinese medicine services and improve operational efficiency [3] Summary by Sections Financial Performance - In the first half of 2025, the company's revenue grew to 1.495 billion yuan, with a net profit of 152 million yuan, driven by improved gross margins and effective cost control [2] - The gross margin increased by 1.2 percentage points to 30.6%, while the management expense ratio decreased by 1.8 percentage points to 6.3% [2] - The number of patient visits increased to 2.747 million, with a stable average spending per visit and a member retention rate of 85% [2] Strategic Initiatives - The company is accelerating its national and international expansion, having established 7 new clinics, bringing the total number of global offline medical institutions to 83 by the end of June 2025 [2] - The development of "AI avatars" is expected to alleviate the supply bottleneck of quality traditional Chinese medicine resources and enhance the company's capacity for revenue growth [3] Profit Forecast and Valuation - The adjusted net profit forecasts for 2025, 2026, and 2027 are 493 million yuan, 594 million yuan, and 708 million yuan respectively [3] - The company is expected to benefit significantly from the aging population and supportive policies in the traditional Chinese medicine sector, alongside the advantages brought by AI [3]

Investment Rating - The report maintains a rating of "Accumulate" for the company [4][6]. Core Views - The company experienced a significant revenue decline of 26.36% year-on-year in H1 2025, with a reported revenue of 260 million yuan and a net profit loss of 40.77 million yuan, indicating a shift from profit to loss [1][2]. - The decline in domestic revenue is attributed to the company's proactive inventory reduction strategy, while overseas business showed growth, particularly in Europe [2]. - The company is focusing on innovation and product development, with the new flagship product AQ-400 expected to enhance competitive differentiation and drive sales growth in 2026 [3][4]. Summary by Sections Financial Performance - In H1 2025, the company reported a revenue of 260 million yuan, down 26.36% year-on-year, and a net profit loss of 40.77 million yuan [1]. - The overall gross margin decreased by 9.07 percentage points to 62.39% due to a higher proportion of lower-margin overseas business [2]. Product Development - The AQ-400 product has received approval and is expected to significantly contribute to sales growth once launched [3]. - The company is investing heavily in R&D, with expenses reaching 73.81 million yuan in H1 2025, accounting for 28.35% of revenue [3]. Profit Forecast and Valuation - The profit forecasts for 2025-2027 have been revised downwards, with expected net profits of 0.06 billion yuan, 0.49 billion yuan, and 0.65 billion yuan respectively [4]. - The company is expected to maintain its leading position in the industry due to its differentiated product offerings [4].

Investment Rating - The report maintains an "Accumulate" rating for the coal mining industry [7]. Core Viewpoints - Recent developments in Indonesia, including large-scale protests, may impact coal production and exports, as Indonesia accounts for 9% of global coal production and 29.8% of global coal trade [2]. - The report highlights a decrease in domestic coal prices, with Qinhuangdao port's average price at 695 RMB/ton, down 1.14% week-on-week [3]. - Coal mine operating rates have declined, with power coal mines at 89.4% and coking coal mines at 84.0% [4]. - The report suggests that recent policies aimed at reducing overproduction may improve long-term coal price expectations, recommending investments in specific coal stocks [5]. Summary by Sections 1. Market Overview - Indonesia's coal production for 2024 is projected at 840 million tons, with exports at 540 million tons [2]. - Domestic coal prices have seen a decline, with notable decreases in both Qinhuangdao and Shaanxi regions [3]. 2. Production and Utilization - The capacity utilization rate for power coal mines is 89.4%, down 2.72 percentage points week-on-week, while coking coal mines are at 84.0%, down 1.37 percentage points [4]. - Daily average pig iron production is reported at 2.4006 million tons, reflecting an 8.7% year-on-year increase [4]. 3. Inventory Levels - Qinhuangdao port coal inventory has increased to 6.1 million tons, up 4.27% week-on-week, while the inventory in the Bohai Rim ports is at 23 million tons, down 1.18% [4]. 4. Investment Recommendations - The report recommends stocks such as China Shenhua, China Coal Energy, and Shaanxi Coal and Chemical Industry, highlighting the potential for significant valuation and profit increases [5].

2025 年 8 月 31 日 公司研究 营收盈利增速改善，零售业务贡献增强 ——招商银行（600036.SH）2025 年半年报点评 买入（维持） 当前价：42.89 元 作者 分析师：王一峰 执业证书编号：S0930519050002 010-57378038 wangyf@ebscn.com 8 月 29 日，招商银行发布 2025 年半年度报告，上半年实现营业收入 1700 亿， 同比下降 1.7%，归母净利润 749 亿，同比小幅增长 0.3%。加权平均净资产收益 率 13.85%，同比下降 1.59pct。 点评： 营收及盈利增速环比改善，零售金融业务贡献占比 56.6%。招行上半年营收、 PPOP 分别同比下降 1.7%、2.6%，降幅较 1Q 均收窄 1.4pct。归母净利润同比 小幅增长 0.3%，增速较 1Q 提升 2.3pct。上半年净利息收入同比增长 1.6%，增 速较 1Q 小幅下降 0.3pct；非息收入同比下降 6.7%，降幅较 1Q 收窄 3.9pct。分 业务条线看，零售金融、批发金融业务营收分别同比下降 0.7%、5.9%，上半年 零售金融业务营收、税前利润占比分别为 56 ...

Investment Rating - The industry is rated as "Buy" [4] Core Insights - In July, the Ministry of Agriculture and Rural Affairs reported a stable yet slightly declining breeding sow inventory at 40.42 million heads, with a significant increase in pig slaughtering volume, reaching 31.66 million heads, a month-on-month increase of 5.3% and a year-on-year increase of 30.4% [1][3] - The average price of commodity pigs showed a slight rebound to 14.84 yuan/kg in July, with a month-on-month increase of 1.9% but a year-on-year decrease of 21.6% [1] - The overall profitability of the industry remained marginal, with average profits per head for large-scale farms at 21 yuan and for smallholders at 6 yuan [1] Summary by Sections 1. Industry Performance - The agricultural sector outperformed the market, with the agricultural index rising by 2.02% compared to the Shanghai Composite Index's 0.84% increase [13] - The livestock farming sector saw a rise of 4.39%, while other sectors like animal health and fisheries experienced declines [13] 2. Key Data Tracking - The average price of live pigs was reported at 13.66 yuan/kg, down 0.65% week-on-week, while the average price of piglets was 27.14 yuan/kg, down 2.3% [22] - The average slaughter weight of pigs decreased to 127.83 kg, with a slight decline of 0.15 kg week-on-week [22] 3. Investment Recommendations - The pig farming sector is expected to enter a long-term profit upcycle, with recommendations for companies such as Muyuan Foods, Wens Foodstuff Group, and Juxing Agriculture [3][68] - The feed and animal health sectors are also highlighted for potential growth, particularly with the recent clinical trials of vaccines [3][68] - The planting chain is recommended for investment due to the upward trend in grain prices, with companies like Suqian Agricultural Development and Beidahuang being noted [3][68] - The pet food sector is experiencing growth, with recommendations for companies like Guibao Pet and Zhongchong Co., Ltd. [3][70]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's performance exceeded expectations, with a revenue of 4.047 billion yuan in the first half of 2025, a year-on-year increase of 29%, and a net profit attributable to shareholders of 211 million yuan, up 60% year-on-year [1] - The growth in revenue is attributed to scale effects and improved cost management, with significant enhancements in operational efficiency [1] - The lithium battery structural components segment saw revenue growth of over 40% year-on-year, with a gross margin of 14.83%, reflecting a 1.62 percentage point increase [2] - The company is positioned as a tier 0.5 manufacturer in the humanoid robot sector, focusing on hardware integration and product iteration [3] Summary by Sections Financial Performance - In Q2 2025, the company reported a revenue of 2.254 billion yuan, a 33% year-on-year increase, and a net profit of 138 million yuan, up 75% year-on-year [1] - The gross margin for Q2 was 16.16%, with a net profit margin of 6.12% [1] Revenue and Profit Forecast - The company expects to achieve net profits of 518 million yuan, 713 million yuan, and 932 million yuan for 2025, 2026, and 2027 respectively, representing growth rates of 103.94%, 37.62%, and 30.74% [3][4] - The projected revenue for 2025 is 9.584 billion yuan, with a growth rate of 34.45% [4] Valuation Metrics - The report provides a price-to-earnings (P/E) ratio forecast of 47 for 2025, decreasing to 26 by 2027 [4] - The company’s return on equity (ROE) is expected to reach 14.85% in 2025, increasing to 18.55% by 2027 [12]

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company's revenue for the first half of 2025 reached 2.163 billion yuan, a year-on-year increase of 14.35%, with a net profit attributable to the parent company of 255 million yuan, up 16.49% year-on-year [1]. - The data center business is expanding rapidly in overseas markets, achieving revenue of 1.299 billion yuan in the first half of 2025, an increase of 8.05% year-on-year, despite a slight decline in gross margin [2]. - The company's energy storage and charging business is recovering, with revenue of 804 million yuan in the first half of 2025, a year-on-year increase of 28.20% [2]. - R&D investment continues to grow, with expenses totaling 132 million yuan in the first half of 2025, a year-on-year increase of 1.51% [3]. Summary by Sections Financial Performance - In Q2 2025, the company achieved revenue of 1.219 billion yuan, a year-on-year increase of 15.00%, and a net profit of 144 million yuan, up 51.58% year-on-year [1]. - The company expects net profits for 2025-2027 to be 563 million, 773 million, and 969 million yuan respectively, with upward adjustments of 6%, 10%, and 10% [3]. Business Segments - The data center business is focusing on overseas expansion, particularly in North America, Europe, and Southeast Asia, while also developing new areas such as edge computing [2]. - The energy storage business is collaborating with major clients and making progress in large-scale storage applications [2]. R&D and Innovation - The company holds a total of 616 valid patents and has been involved in drafting or revising 133 national and industry standards [3]. - The R&D strategy emphasizes market orientation and technology-driven innovation to enhance product competitiveness [3].